Clinical Trial Update: A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice [NA]

View source ↗

Summary

A post-market evaluation study of LipiFlow treatment in cataract surgery practice has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataracts
• Meibomian Gland Dysfunction

Drugs mentioned

• LipiFlow

Snippet

Sponsor: Johnson & Johnson Surgical Vision, Inc. | Conditions: Cataracts, Meibomian Gland Dysfunction (MGD) | NA | Status: COMPLETED | Results posted: 2021-04-27